Neurocrine Biosciences Announces Upcoming Financial Conference Call
Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a leader in the field of neuroscience, is excited to inform stakeholders about its scheduled conference call and webcast. The event is set for the afternoon of July 30, where financial results for the second quarter of 2025 will be shared. This moment allows the organization to review its achievements and future direction.
Details of the Conference Call and Webcast
On July 30, 2025, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), Neurocrine will host its conference call. A press release summarizing the second-quarter results will be made available at 1:00 p.m. PT (4:00 p.m. ET) on the same day. The call will offer insights into the company’s quarterly performance and ongoing projects.
Participants can access the call through a simple dial-in process:
- Domestic Call Number: 800-225-9448
- International Call Number: 203-518-9708
- Conference ID: NBIX
Additionally, those interested in the webcast can find it on the Neurocrine Biosciences website within the Investors section. This will provide an opportunity for stakeholders to engage with the information in real-time and revisit the discussion later, as it will be available for replay approximately one hour post-event.
About Neurocrine Biosciences
Neurocrine Biosciences stands at the forefront of neuroscience-focused biopharmaceuticals with a commitment to serving people who need innovative solutions for under-addressed conditions. Their mission is to relieve suffering through the development of transformative therapies aimed at neurological, neuroendocrine, and neuropsychiatric disorders.
With a robust portfolio, Neurocrine boasts several FDA-approved therapies targeting various conditions, including treatments for tardive dyskinesia and chorea linked to Huntington's disease, among others. Moreover, their extensive pipeline is poised to deliver additional therapies, with numerous candidates currently in mid- to late-stage clinical development. This ongoing commitment underlines their belief in the power of brave science to enable positive health outcomes.
Innovative Solutions for Complex Conditions
During the upcoming conference call, stakeholders can also look forward to hearing about advancements in Neurocrine's therapeutic areas. Their focus remains on leveraging unique insights into neuroscience to develop patient-centric solutions. Highlights from the recent clinical trials and developmental milestones will likely be discussed, enlightening investors about the company's trajectory and goals.
Follow Neurocrine Biosciences
For those wishing to engage actively with Neurocrine Biosciences' journey, the company encourages following their updates across social media platforms, including LinkedIn, X, and Facebook. These channels are great resources for the latest news, research findings, and insights into their ongoing missions.
Frequently Asked Questions
What will Neurocrine discuss during the conference call?
Neurocrine will cover its second quarter financial results and provide updates on ongoing projects and therapies in development.
When is the financial conference call scheduled?
The call is slated for July 30, 2025, at 1:30 p.m. Pacific Time.
How can I access the conference call?
Participants can dial in using the provided domestic or international number to join the call.
Where can I find more information about Neurocrine?
More information is available on Neurocrine Biosciences' official website under the Investors section.
What therapies does Neurocrine Biosciences focus on?
The company focuses on treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with a diverse portfolio and pipeline.
